Loading...
Peanut allergy affects 2% of children and is the most common cause of fatal food-induced anaphylaxis. Several studies have shown that patients can be desensitized with peanut oral immunotherapy (OIT; e.g., NEJM JW Pediatr Adolesc Med Jan 2019 and N Engl J Med 2018; 379:1991). Now, researchers have performed a systematic review of 12 randomized, controlled trials (with >1000 mostly pediatric patients) to examine how OIT affects quality of life and anaphylaxis incidence.
Median starting dose of peanut protein was 0.5 mg (1/600th of a peanut), with a median target dose of 2000 mg (6–7 peanuts) escalated during a median 31 weeks. Patients in the OIT groups experienced significantly more anaphylactic reactions than did an untreated historical coh…